Hepatitis C-Associated Rheumatic Disorders

Rheumatic Disease Clinics of North America

Volumn 35, Issue 1, 2009, Pages 111-123

  Buskila, Dan ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Arthritis; Autoimmunity; Hepatitis C virus; Musculoskeletal manifestations; Rheumatic disorders

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PENICILLAMINE; RIBAVIRIN; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ABSENCE OF SIDE EFFECTS; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FIBROMYALGIA; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MONOTHERAPY; MYALGIA; PARESTHESIA; PATHOGENESIS; POLYARTERITIS NODOSA; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SPECTROSCOPY; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS;

ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; RHEUMATIC DISEASES;

EID: 65949122748     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.03.005     Document Type: Review

References (77)

1. Cacoub P., Renou C., Rosenthal E., et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Medicine (Baltimore) 79 1 (2000) 47-56
2. Ramos-Casals M., and Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 17 4 (2005) 447-455
3. Sterling R.K., and Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep 8 1 (2006) 53-59
4. Buskila D. Hepatitis C-associated arthritis. Curr Opin Rheumatol 12 4 (2000) 295-299
5. Lormeau C., Falgarone G., Roulot D., et al. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 73 6 (2006) 633-638
6. Ramos-Casals M., Jara L.J., Medina F., et al. Systemic autoimmune diseases coexisting with chronic hepatitis C virus infection (the HIS PAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med 257 6 (2005) 549-557
7. Buskila D., Shnaider A., Neumann L., et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus-infected Israeli patients. Semin Arthritis Rheum 28 2 (1998) 107-113
8. Nissen M.J., Fontanges E., Allam Y., et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology 44 8 (2005) 1016-1020
9. Stefanova-Petrova D.V., Tzvetanska A.H., Naumova E.J., et al. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol 13 48 (2007) 6518-6528
10. Lovy M.R., Starkebaum G., and Uberoi S. Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 23 6 (1996) 979-983
11. Lee Y.H., Ji J.D., Yeon J.E., et al. Cryoglobulinemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis 57 12 (1998) 728-731
12. Moder K.G., and Lindor K. Musculoskeletal symptoms associated with hepatitis C. [abstract]. Arthritis Rheum 38 Suppl (1995) S200
13. Romero Portales M., De Diego Lorenzo A., Rivera J., et al. Rheumatologic and autoimmune manifestations in patients with chronic hepatitis C virus infection. Rev Esp Enferm Dig 89 8 (1997) 591-598
14. Cacoub P., Poynard T., Ghillani P., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Arthritis Rheum 42 10 (1999) 2204-2212
15. Rivera J., Garcia-Monforte A., Pineda A., et al. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 26 9 (1999) 420-424
16. Zuckerman E., Keren D., Rosenbaum M., et al. Hepatits C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 18 5 (2000) 579-584
17. Rosner I., Rosenbaum M., Toubi E., et al. The case for hepatitis C arthritis. Semin Arthritis Rheum 33 6 (2004) 375-387
18. Zuckerman E., Yeshurun D., and Rosner I. Management of hepatitis C virus-related arthritis. BioDrugs 15 9 (2001) 573-584
19. Oliveri I., Palazzi C., and Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin North Am 29 1 (2003) 111-122
20. Haddad J., Deny P., Munz-Gotheil C., et al. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 339 8789 (1992) 321-323
21. Ramos-Casals M., Loustaud-Rati V., Devita S., et al. Sjogren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 84 2 (2005) 81-89
22. Brito-Zeron P., Ramos-Casals M., Nardi N., et al. Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence in 237 patients. Medicine (Baltimore) 84 2 (2005) 90-97
23. *02. Eur J Gastroenterol Hepatol 19 6 (2007) 493-498
24. Ramos-Casals M., De Vita S., and Tzioufas A.G. Hepatitis C virus, Sjogren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev 4 1 (2005) 8-15
25. Lunel F., Musset L., Caccoub P., et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 106 5 (1994) 1291-1300
26. Bryce A.H., Kyle R.A., Dispenzieri A., et al. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 81 7 (2006) 511-518
27. Saadoun D., Landau D.A., Calabrese L.H., et al. Hepatitis C-associated mixed cryoglobulinemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology 46 8 (2007) 1234-1242
28. Pileri P., Umematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 5390 (1998) 938-941
29. De Vita S., Quartuccio L., and Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?. Autoimmun Rev 8 2 (2008) 95-99
30. Antonelli A., Ferri C., Fallahi P., et al. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 57 9 (2008) 1270-1277
31. Antonelli A., Ferri C., Fallahi P., et al. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 103 10 (2008) 2488-2494
32. Antonelli A., Ferri C., Fallahi P., et al. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinemia and hepatitis C. Dig Liver Dis 41 1 (2009) 42-48
33. Ferri C., Sebastiani M., Giuqqioli D., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33 6 (2004) 355-374
34. Buskila D., Atzeni F., and Sarzi Puttini P. Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev 8 1 (2008) 41-43
35. Ablin J.N., Shoenfeld Y., and Buskila D. Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. J Autoimmun 27 3 (2006) 145-152
36. Buskila D., Shnaider A., Neumann L., et al. Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch Intern Med 157 21 (1997) 2497-2500
37. Rivera J., de Diego A., Trinchet M., et al. Fibromyalgia-associated hepatitis C virus infection. Br J Rheumatol 36 9 (1997) 981-985
38. Goulding C., O' Connell P., and Murray F.E. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 13 5 (2001) 507-511
39. Kozanoglu E., Canataroglu A., Abayli B., et al. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int 23 5 (2003) 248-251
40. Narvaez J., Nolla J.M., and Valverde-Garcia J. Lack of association of fibromyalgia with hepatitis C virus infection. J Rheumatol 32 6 (2005) 1118-1121
41. Palazzi C., D'Amico E., D'Angelo S., et al. Hepatitis C virus infection in Italian patients with fibromyalgia. Clin Rheumatol 27 1 (2008) 101-103
42. Poynard T., Caccoub P., Ratziu V., et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 9 4 (2002) 295-303
43. Buskila D., Sikuler E., and Shoenfeld Y. Hepatitis C virus, autoimmunity and rheumatic disease. Lupus 6 9 (1997) 685-689
44. Lenzi M., Bellentani S., Saccoccio G., et al. Prevalence of non-organ specific autoantibodies and chronic liver disease in the general population: a nested case control study of the Dionysos cohort. Gut 45 3 (1999) 435-441
45. Dudek A., Dudziak M., Sulek M., et al. [Serological markers of arthritis in patients with chronic viral hepatitis]. Pol Merkur Lekarski 20 118 (2006) 404-407 [in Polish]
46. Reddy K.R., Krawitt E.L., Homberg J.C., et al. Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat 2 4 (1995) 175-179
47. Kessel A., Elias G., Pavlotzky E., et al. Anti -C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity. Hum Immunol 68 10 (2007) 844-848
48. Christodoulou D., Christou L., Zervou E., et al. Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha. Hepatogastroenterology 54 78 (2007) 1761-1765
49. Wu C.S., Hu C.Y., and Hsu P.N. Anti SSB/La antibody is negatively associated with HLA-DR2 in chronic hepatitis C infection. Clin Rheumatol 27 3 (2008) 365-368
50. Alpa M., Ferrero B., Cavallo R., et al. Anti-neuronal antibodies in patients with HCV-related mixed cryoglobulinemia. Autoimmun Rev 8 1 (2008) 56-58
51. Lienesch D., Morris R., Metzger A., et al. Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 32 3 (2005) 489-493
52. Gehring S., Kullmer U., Koeppelmann S., et al. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World J Gastroenterol 12 36 (2006) 5787-5792
53. Ramos-Casals M., Pares A., Jara L.J., et al. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J Viral Hepat 12 6 (2005) 648-654
54. Cervera R., Asherson R.A., Acevedo M.L., et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 63 10 (2004) 1312-1317
55. Ramos-Casals M., Cervera R., Laqrutta M., et al. Clinical features related to antiphospholipid syndrome in patients with chronic viral infection (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis 38 7 (2004) 1009-1016
56. Ramos-Casals M., Font J., Garcia-Carrasco M., et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 43 12 (2000) 2801-2806
57. Perlemuter G., Cacoub P., Sbai A., et al. Hepatitis C virus infection in systemic lupus erythematosus: a case control study. J Rheumatol 30 7 (2003) 1473-1478
58. Ahmed M.M., Berney S.M., Wolf R.E., et al. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 331 5 (2006) 252-256
59. Sene D., Limal N., and Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 19 3-4 (2004) 357-381
60. Cacoub P., Maisonobe T., Thibault V., et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 28 1 (2001) 109-118
61. de Dios Garcia-Diaz J., Garcia-Sanchez M., Arcos P., et al. Polyarteritis nodosa after interferon treatment for chronic hepatitis C. J Clin Virol 32 2 (2005) 181-182
62. Palazzi C., D'Angelo S., and Olivieri I. Hepatitis C virus-related arthritis. Autoimmun Rev 8 1 (2008) 48-51
63. Antonelli A., Ferri C., Galeazzi M., et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 26 1 Suppl 48 (2008) S39-S47
64. Zuckerman E., Keren D., Slobodin G., et al. Treatment of refractory symptomatic hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon alpha. J Rheumatol 27 9 (2000) 2172-2178
65. Mazzaro C., Zorat F., Caizzi M., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42 5 (2005) 632-638
66. Cacoub P., Saadoun D., Limal N., et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52 3 (2005) 911-915
67. Joshi S., Kuczynski M., and Heathcote E.J. Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulinemia. Dig Dis Sci 52 9 (2007) 2410-2417
68. Galeazzi M., Bellisai F., Giannitti C., et al. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 1110 9 (2007) 544-549
69. Bellisai F., Giannitti C., Donvito A., et al. Combination therapy with cyclosporine A and anti TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 26 7 (2007) 1127-1129
70. Linardaki G., Katsarou O., Ioannidou P., et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 34 6 (2007) 1353-1355
71. Romero-Maté A., Garcia Donoso C., and Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 8 3 (2007) 143-155
72. Ferri C., Ferraccioli G., Ferrari D., et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 35 10 (2008) 1944-1949
73. Cavazzana I., Ceribelli A., Cattaneo R., et al. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8 2 (2008) 104-106
74. Cansu D.U., Kalifoglu T., and Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35 3 (2008) 421-424
75. Quartuccio L., Soardo G., Romano G., et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology (oxford) 45 7 (2006) 842-846
76. Zaja F., Devita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 10 (2003) 3827-3834
77. De Vita S., Quartuccio L., Fabris M., et al. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 39 Suppl 1 (2007) S122-S128